3 recruiting, 1 withdrawn. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 3, Withdrawn 1 |
Follow NMIBC: new trials by email Literature Review of NMIBC trials Research Report on NMIBC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC SHR-1501 for Injection, BCG for Injection, Epirubicin Hydrochloride for Injection - NMIBC | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 236 | 2026-07-13 | 2026-07-20 |
| 1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder Tumors En Bloc Resection of Bladder Tumor, Trans Urethral Resection of Bladder Tumor - NMIBC, TCC | Phase 3 | Recruiting | dmitry enikeev | 136 | 2026-06-08 | 2026-10-27 |
| ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer BCG (50 mg) plus ANKTIVA (400 µg), BCG (50 mg) - NMIBC | Phase 3 | Withdrawn | ImmunityBio, Inc. | 2026-05-15 | 2026-05-19 | |
| DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC Active Comparator: BCG induction and maintenance, DV + BCG induction and maintenance - Bladder (Urothelial, Transitional Cell) Cancer, NMIBC | Phase 3 | Recruiting | Fudan University | 182 | 2025-12-01 | 2026-07-21 |
Non-Muscle Invasive Bladder Neoplasms (4) · Neoplasms (1)
Carcinoma (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Urinary Bladder Diseases (4) · Urinary Bladder Neoplasms (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Urologic Diseases (4) · Urologic Neoplasms (4) · Neoplasms (3)
Epirubicin (1) · Gemcitabine (1) · Injections (1) · Maintenance (1) · Mitomycin (1) · hydroxycamptothecinum (1) · pirarubicin (1)
Fudan University (1) · ImmunityBio, Inc. (1) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1) · dmitry enikeev (1)
China (2) · Israel (1)